[1] |
ZHU N, ZHANG D, WANG W, et al.A novel coronavirus from patients with pneumonia in China, 2019[J].N Engl J Med, 2020, 382(8):727. |
[2] |
王帮璇, 元永艇, 张丽, 等.新型冠状病毒肺炎死亡病例变化趋势及其从发病到死亡时间的特征分析[J].蚌埠医学院学报, 2020, 45(2):141. |
[3] |
JIANG F, YANG J, ZHANG Y, et al.Angiotensin-converting enzyme 2 and angiotensin 1-7:novel therapeutic targets[J].Nat Rev Cardiol, 2014, 11(7):413. |
[4] |
DOMINICI FP, BURGHI V, MUÑOZ MC, et al.Modulation of the action of insulin by angiotensin-(1-7)[J].ClinSci (Lond), 2014, 126(9):613. doi: 10.1042/CS20130333 |
[5] |
国家卫生健康委员会.关于印发新型冠状病毒肺炎诊疗方案(试行第七版)的通知[R].2020-03-04. |
[6] |
王春晖, 李晓宇, 许青, 等.新型冠状病毒肺炎与血管紧张素转化酶2的研究现状[J].中国医院药学杂志, 2020.http://kns.cnki.net/kcms/detail/42.1204.r.20200310.1842.002.html. |
[7] |
BORNSTEIN SR, DALAN R, HOPKINSD, et al.Endocrine and metabolic link to coronavirus infection[J].Nat Rev Endocrinol, 2020.doi:10.1038/s41574-020-0353-9. |
[8] |
FANG L, KARAKIULAKIS G, ROTH M.Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?[J].Lancet Respir Med, 2020, 8(4):e21. doi: 10.1016/S2213-2600(20)30116-8 |
[9] |
罗蒙, 江波, 徐鸿婕, 等.新型冠状病毒肺炎患者死亡影响因素分析[J].中草药, 2020, 51(6):1450. |
[10] |
中国疾病预防控制中心新型冠状病毒肺炎应急响应机制流行病学组.新型冠状病毒肺炎流行病学特征分析[J].中华流行病学杂志, 2020, 41(2):145. |
[11] |
ONDER G, REZZA G, BRUSAFERRO S.Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy[J].JAMA, 2020.doi:10.1001/jama.2020.4683. |
[12] |
CHENG H, WANG Y, WANG GQ.Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19[J].J Med Virol, 2020.doi:10.1002/jmv.25785. |
[13] |
CHAPPELLMC.Does ACE2 contribute to the development of hypertension?[J].Hypertens Res, 2010, 33(2):107. doi: 10.1038/hr.2009.207 |
[14] |
SOUTH AM, DIZ D, CHAPPELL MC.COVID-19, ACE2 and the Cardiovascular Consequences[J].Am J Physiol Heart Circ Physiol, 2020, 318(5):H1084. doi: 10.1152/ajpheart.00217.2020 |
[15] |
YANG JK, FENG Y, YUAN MY, et al.Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS[J].Diabet Med, 2006, 23(6):623. |
[16] |
冯波.新型冠状病毒肺炎疫情期间糖尿病患者的管理及注意事项[J].同济大学学报(医学版), 2020, 41(1):1. |
[17] |
ZHOU T, HU Z, YANG S, et al.Role of adaptive and innate immunity in type 2 diabetes mellitus[J].J Diabetes Res, 2018, 2018:7457269. |
[18] |
YANG JK, LIN SS, JI XJ, et al.Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes[J].Acta Diabetol, 2010, 47(3):193. |